Cardinal Analytx has raised $20.6m of a targeted $29.3m, adding to a 2017 series A round that included Premera Blue Cross in 2017.

Based on research at University of Notre Dame, Happe Spine is working on implants for interbody spinal fusion.

Indiana University Philanthropic Venture Fund has made its tenth investment, putting $200,000 into Confluence Pharmaceuticals.

Stanford-StartX Fund has supported a $4m round for Imprimed, which is working on precision cancer treatments for dogs.

Willow Biosciences is the result of a three-way merger between University of Calgary spinout Epimeron, BioCan Technologies and CSE-listed Makena Resources.

The biopharmaceutical company, formerly known as Pronutria Biosciences and backed by Nestlé Health Science, has filed for an $86.3m offering following $172m of funding.

Pfizer is the largest shareholder of Alzheimer's drug developer Cortexyme, which has filed to raise up to $86.3m in its initial public offering.

Stanford spinout Cardinal Analytx has raised $20.6m out of a targeted $29.3m, adding to a $6.1m series A round backed by Stanford-StartX Fund in 2017.

Asklepios BioPharmaceutical, based on work by UNC Chapel Hill professors Jude Samulski and Xiao Xiao, has secured $235m in funding co-led by TPG Capital and Vida Ventures.

PureTech Health and Mitsubishi Tanabe Pharma took part in the Merck Group-led series A round, which will fund work developing Sonde's voice-based medical monitoring technology.